Xenon: XEN1101 Phase 2b ‘X-TOLE’ Clinical trial results published

Xenon Pharmaceuticals announced the medical journal JAMA Neurology has published peer-reviewed efficacy and safety results from the X-TOLE Phase 2b randomized clinical trial of XEN1101, a novel potassium channel opener, in adults with focal epilepsy. Importantly, the efficacy and safety findings of this clinical trial supported the further clinical development in epilepsy of XEN1101, which is currently being evaluated in Phase 3 clinical trials in patients with focal onset seizures FOS and primary generalized tonic-clonic seizures. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are pleased to report that the peer-reviewed results from our Phase 2b X-TOLE study of XEN1101 in adults with focal epilepsy have been published in the prestigious JAMA Neurology journal. With a cohort of patients now on drug for more than four years as we continue to gather data from our ongoing open-label extension study, XEN1101 continues to demonstrate its efficacy through sustained seizure reduction and a compelling product profile with once-daily dosing with food and no titration required.